<DOC>
	<DOC>NCT02402595</DOC>
	<brief_summary>The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor, itraconazole, on the steady-state PK of AVP-923 and AVP-786.</brief_summary>
	<brief_title>Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts</brief_title>
	<detailed_description>A Phase 1, single-center, randomized, double-blind, double-dummy drug interaction study.</detailed_description>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Healthy adult males and females, 18 to 55 years of age Body Mass Index (BMI) ≥19 and ≤30 kg/m2 (for both males and females) History or presence of significant disease History of substance abuse or dependence (except caffeine), or treatment for substance use disorder(s) within the year prior to screening or within 6 months for nicotine including ecigarettes Use of any tobaccocontaining or nicotinecontaining products within 6 months prior to the first dose Use of any prescription or the overthecounter medications within 14 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>deuterated dextromethorphan</keyword>
	<keyword>dextromethorphan</keyword>
	<keyword>dextromethorphan with quinidine</keyword>
	<keyword>deuterated dextromethorphan with quinidine</keyword>
	<keyword>itraconazole</keyword>
</DOC>